2023
Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study
Sherman G, Lamb G, Sharma T, Lloyd E, Nagel J, Dandam N, Oliveira C, Sheikha H, Anosike B, Lee P, Vora S, Patel K, Sue P, Rubbab B, Yarbrough A, Ganapathi L, Nakamura M. Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study. Journal Of The Pediatric Infectious Diseases Society 2023, 12: 152-155. PMID: 36928172, PMCID: PMC10112679, DOI: 10.1093/jpids/piac124.Peer-Reviewed Original ResearchClinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae
Habet V, Oliveira C. Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae. Seminars In Respiratory And Critical Care Medicine 2023, 44: 066-074. PMID: 36646086, PMCID: PMC9926930, DOI: 10.1055/s-0042-1759566.Commentaries, Editorials and LettersConceptsClinical epidemiologyCOVID-19Pediatric coronavirus disease 2019Pediatric COVID-19Multisystem inflammatory syndromeAcute respiratory illnessCoronavirus disease 2019 (COVID-19) pandemicCoronavirus disease 2019Disease 2019 pandemicQuality of lifeHealth care systemBenign illnessCardiogenic shockInflammatory syndromeLong COVIDPostinfectious sequelaePediatric deathsRespiratory illnessPostacute sequelaeDisease 2019Mortality rateConsiderable burdenAge groupsCare systemSequelae
2022
Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents
Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, Olivero RM, Oliveira CR, James SH, Morton TH, Maron GM, Young JL, Orscheln RC, Schwenk HT, Bio LL, Willis ZI, Lloyd EC, Hersh AL, Huskins CW, Soma VL, Ratner AJ, Hayes M, Downes K, Chiotos K, Grapentine SP, Wattier RL, Lamb GS, Zachariah P, Nakamura MM. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. Journal Of The Pediatric Infectious Diseases Society 2022, 11: 177-185. PMID: 35107571, PMCID: PMC8903349, DOI: 10.1093/jpids/piab124.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyPediatric infectious diseasesAntibody therapyEmergency use authorizationSevere diseasePostexposure prophylaxisHigh riskCOVID-19Severe acute respiratory syndrome coronavirus 2Certain high-risk conditionsSpecific monoclonal antibody therapyAcute respiratory syndrome coronavirus 2Infectious diseasesRespiratory syndrome coronavirus 2Moderate COVID-19Pediatric critical care medicineSyndrome coronavirus 2Coronavirus disease 2019Critical care medicineHigh-risk conditionsSeries of teleconferencesHigh-risk exposureBamlanivimab monotherapyInfusion reactionsControlled Trials
2021
The clinical epidemiology of coronavirus disease 2019 in children and adolescents mirrors the widening gap in healthcare disparities
Zirinsky E, Paintsil E, Oliveira CR. The clinical epidemiology of coronavirus disease 2019 in children and adolescents mirrors the widening gap in healthcare disparities. Current Opinion In Pediatrics 2021, 33: 281-285. PMID: 33871422, PMCID: PMC8635086, DOI: 10.1097/mop.0000000000001018.Commentaries, Editorials and LettersConceptsClinical epidemiologyRespiratory diseaseSARS-CoV-2-related deathAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicSevere lower respiratory diseaseHealth disparitiesSARS-CoV-2 infectionLongstanding health disparitiesKawasaki-like syndromeLower respiratory diseaseCoronavirus 2 pandemicCoronavirus disease 2019Upper respiratory diseaseSARS-CoV-2Ethnic health disparitiesPandemics/epidemicsCardiovascular shockInfluenza seasonDisease 2019Healthcare disparitiesUS populationEthnic disparitiesHispanic childrenMore childrenInitial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents
Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, Dulek DE, Waghmare A, Olivero R, Downes KJ, James SH, Pinninti SG, Yarbrough A, Aldrich ML, MacBrayne CE, Soma VL, Grapentine SP, Oliveira CR, Hayes M, Kimberlin DW, Jones SB, Bio LL, Morton TH, Hankins JS, Marόn-Alfaro G, Timberlake K, Young JL, Orscheln RC, Schwenk HT, Goldman DL, Groves HE, Huskins WC, Rajapakse NS, Lamb GS, Tribble AC, Lloyd E, Hersh AL, Thorell EA, Ratner AJ, Chiotos K, Nakamura MM. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. Journal Of The Pediatric Infectious Diseases Society 2021, 10: 629-634. PMID: 33388760, PMCID: PMC7799019, DOI: 10.1093/jpids/piaa175.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyHigh-risk groupAntibody therapyEmergency use authorizationCOVID-19Moderate coronavirus disease 2019Pediatric intensive care medicinePediatric-specific evidenceTreatment of mildPediatric infectious diseasesHigh-quality evidenceCoronavirus disease 2019Intensive care medicineSeries of teleconferencesREGN-COV2Infusion reactionsPediatric HematologyTimely administrationRisk factorsRoutine administrationDisease 2019Severe diseaseCare medicineHigh riskModest benefit
2020
Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Children in a Large Regional US Health System During the Coronavirus Disease 2019 Pandemic.
Peaper DR, Murdzek C, Oliveira CR, Murray TS. Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Children in a Large Regional US Health System During the Coronavirus Disease 2019 Pandemic. The Pediatric Infectious Disease Journal 2020, 40: 175-181. PMID: 33399431, PMCID: PMC8852689, DOI: 10.1097/inf.0000000000003024.Peer-Reviewed Original ResearchConceptsYale New Haven Health SystemSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Subset of childrenPediatric casesHealth systemCycle threshold valuesCoronavirus 2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNACross-sectional time-series studyCoronavirus disease 2019 (COVID-19) testingPositive pediatric casesSimilar cycle threshold valuesCoronavirus disease 2019 (COVID-19) pandemicUpper respiratory tractCoronavirus disease 2019Large health systemYears of ageDisease 2019 pandemicUS health systemAmbulatory locationsVirology resultsAsymptomatic childrenMulticenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, Yarbrough A, Abzug MJ, MacBrayne CE, Soma VL, Dulek DE, Vora SB, Waghmare A, Wolf J, Olivero R, Grapentine S, Wattier RL, Bio L, Cross SJ, Dillman NO, Downes KJ, Oliveira CR, Timberlake K, Young J, Orscheln RC, Tamma PD, Schwenk HT, Zachariah P, Aldrich ML, Goldman DL, Groves HE, Rajapakse NS, Lamb GS, Tribble AC, Hersh AL, Thorell EA, Denison MR, Ratner AJ, Newland JG, Nakamura MM. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal Of The Pediatric Infectious Diseases Society 2020, 10: 34-48. PMID: 32918548, PMCID: PMC7543452, DOI: 10.1093/jpids/piaa115.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMechanical ventilationCOVID-19Pediatric infectious disease physiciansInvasive mechanical ventilationSupplemental oxygen requirementInfectious disease physiciansUse of hydroxychloroquineUse of remdesivirNoninvasive mechanical ventilationUse of antiviralsCoronavirus disease 2019Series of teleconferencesPotential antiviral activityLopinavir-ritonavirCritical illnessDisease physiciansMost patientsSupportive careMembrane oxygenationPediatric patientsAntiviral therapyMild courseSevere illnessIll childrenClinical trials